February 25, 2009 - CardioVascular BioTherapeutics Inc. (CVBT) has opened patient enrollment at two additional hospitals in the U.S. for its ACORD Phase II clinical trial for the treatment of severe coronary heart disease.
The newest sites are Florida Hospital/Cardiovascular Institute in Orlando and Chandler Regional Medical Center and Mercy Gilbert Medical Center serving the Phoenix, AZ metropolitan area.
Mercy Hospital Fairfield (Ohio) and The Christ Hospital in Cincinnati, OH were first to open for enrollment in early September, and are working in collaboration to screen and treat patients in the trial. They treated their first patient in support of the trial in mid November 2008.
CVBT is a biopharmaceutical company developing human FGF-1 for cardiovascular diseases characterized by inadequate blood flow to a tissue or organ. In addition to the Phase II trial it is conducting in patients with severe coronary heart disease, the company has two FDA-authorized clinical trials in the areas of impaired wound healing seen in diabetics and in patients suffering from peripheral artery disease of the legs.
CVBT now has seven sites that are open for enrollment and intends to announce additional sites as they open for screening patents.
For more information: www.cvbt.com
April 24, 2024 
